We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study To Evaluate The Efficacy And Safety Of Betahistine Mesilate In The Treatment Of Patients With Vertigo Caused By Cerebral Infarction In Posterior Circulation

This study has been withdrawn prior to enrollment.
(Due to poor enrollment, this study was withdrawn/ terminated.)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00474409
First Posted: May 16, 2007
Last Update Posted: June 5, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Eisai Inc.
  Purpose
The purpose of this study is to determine the efficacy and safety of Betahistine Mesilate in the treatment of patients with vertigo caused by Cerebral Infarction in posterior circulation.

Condition Intervention Phase
Vertigo Drug: Merislon Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Multicenter, Placebo-Controlled, Double-Blind Study To Evaluate The Efficacy And Safety Of Betahistine Mesilate In The Treatment Of Patients With Vertigo Caused By Cerebral Infarction In Posterior Circulation

Resource links provided by NLM:


Further study details as provided by Eisai Inc.:

Primary Outcome Measures:
  • Changes in the European Evaluation of Vertigo (EEV) scale in 4 weeks. [ Time Frame: 4 weeks ]

Secondary Outcome Measures:
  • The duration of the vertigo symptom.

Enrollment: 0
Study Start Date: May 2007
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

1. Patients that have a clinical diagnosis of posterior circulation infarction and vertigo occurring within 1 month after the infarction.

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00474409


Locations
China, Beijing
Beijing Tiantan Hospital
Beijing, Beijing, China, 100050
Beijing Hospital
Beijing, Beijing, China, 100730
China, Shanghai
Shanghai Renji Hospital
Shanghai, Shanghai, China, 20001
Shanghai Huashan Hospital
Shanghai, Shanghai, China, 200040
Sponsors and Collaborators
Eisai Inc.
Investigators
Principal Investigator: Wang Yong Jun Beijing Tiantan Hospital
  More Information

Responsible Party: Eisai Inc.
ClinicalTrials.gov Identifier: NCT00474409     History of Changes
Other Study ID Numbers: MRS-CHN-001
First Submitted: May 3, 2007
First Posted: May 16, 2007
Last Update Posted: June 5, 2017
Last Verified: May 2017

Keywords provided by Eisai Inc.:
Vertigo
Posterior circulation infarction

Additional relevant MeSH terms:
Vestibular Diseases
Infarction
Cerebral Infarction
Vertigo
Dizziness
Ischemia
Pathologic Processes
Necrosis
Brain Infarction
Brain Ischemia
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Stroke
Vascular Diseases
Cardiovascular Diseases
Labyrinth Diseases
Ear Diseases
Otorhinolaryngologic Diseases
Neurologic Manifestations
Signs and Symptoms
Sensation Disorders
Betahistine
Vasodilator Agents
Histamine Agonists
Histamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs


To Top